SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer.
SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio.
For more information, please visit www.springworkstx.com.
SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio.
For more information, please visit www.springworkstx.com.
Location: United States, Connecticut, Stamford
Employees: 201-500
Total raised: $453M
Founded date: 2017
Investors 5
| Date | Name | Website |
| - | Bain Capit... | baincapita... |
| - | OrbiMed | orbimed.co... |
| - | Perceptive... | perceptive... |
| - | HBM Partne... | hbmpartner... |
| - | Bain Capit... | baincapita... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.09.2022 | - | $225M | - |
| 02.04.2019 | Series B | $125M | - |
| 25.09.2017 | Series A | $103M | - |
Mentions in press and media 29
| Date | Title | Description |
| 25.04.2025 | The Evolving Landscape of Oncology: Innovations and Challenges | The world of oncology is a battleground. New weapons are being forged daily, yet the fight against cancer remains daunting. Recent developments from Antengene Corporation and Gilead Sciences highlight both the promise and the pitfalls in th... |
| 24.04.2025 | Gilead reports quarterly profit, revenue flat as cancer sales slow | Gilead reports quarterly profit, revenue flat as cancer sales slow By Deena BeasleyApril 24, 20258:09 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link Gilead Sciences is seen in Oceanside, Califo... |
| 24.04.2025 | Germany's Merck nears deal for SpringWorks, source says | Germany's Merck nears deal for SpringWorks, source says By ReutersApril 24, 20257:54 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link The logo of Merck pharmaceutical company is seen on the wall ... |
| 11.02.2025 | Merck's Bold Move: Aiming for Growth Through Acquisition | In the world of pharmaceuticals, the quest for growth often leads to strategic acquisitions. Recently, Merck KGaA, the German healthcare giant, has set its sights on Springworks Therapeutics, a U.S. biotech firm specializing in cancer and r... |
| 10.02.2025 | Exclusive: Germany's Merck in advanced talks to acquire US biotech firm Springworks | Exclusive: Germany's Merck in advanced talks to acquire US biotech firm Springworks By Sabrina Valle and Patricia WeissFebruary 10, 20258:43 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link Item ... |
| 23.05.2024 | How a 28-Year-Old Woman Kept Her Sense of Adventure Following a Rare Disease Diagnosis | (BPT) - In 2018, a vibrant young woman with a passion for theater and education set off on the quest of a lifetime: spending a month walking 500 miles on the Camino de Santiago pilgrimage from France to Spain. Christina K. was also at the b... |
| 16.11.2023 | How do we know Alzheimer’s drugs ‘work’? | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with an update on a thwarted gene therapy study, a head-to-head fight in GLP-1, ... |
| 07.09.2022 | GSK helps SpringWorks to double payday from boosted combo deal as it also reels $225M in new funding | It’s a good day to be the CFO of SpringWorks Therapeutics. The precision medicine biotech has not only secured $225 million in funding, but also banked a further $75 million equity investment as part of an expanded agreement with GSK. First... |
| 07.09.2022 | SpringWorks Therapeutics Announces $225 Million Private Placement Financing | - |
| 13.12.2021 | Don’t let ‘shelved assets’ gather dust. Make them into new lifesaving drugs | Life-science companies have changed the world with the breakthrough vaccines and therapeutics they created — and continue to create — to combat Covid-19. And thanks to the new technologies they developed during the pandemic, new medicines f... |
Show more